|Bid||2.2200 x 1200|
|Ask||0.0000 x 900|
|Day's Range||2.8000 - 2.9900|
|52 Week Range||1.2300 - 4.2300|
|Beta (5Y Monthly)||-3.51|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 17, 2020 - Feb 22, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
HIGH POINT, N.C., Feb. 10, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (VTVT) today announced positive results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D). The 12-week trial investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 people with type 1 diabetes on optimized insulin therapy. The study was conducted with support from JDRF International (JDRF), the leading provider of T1D research funding globally.
HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes (T1D) on Monday, February 10th at 7:00am ET. In June 2019, the company announced positive results from Part 1 of the Phase 2 study that showed a statistically significant reduction in HbA1c without increases in ketoacidosis or hypoglycemia. Part 1 had no serious adverse event reported, and no report of diabetic ketoacidosis or severe hypoglycemia.
If Mjalli proves successful in High Point, then by the end of the next decade, the Triad’s biomedical and clinical research industry will look nothing like it does today.
vTv Thereaputics' clinical trial for azeliragon, a drug created by the company to slow or halt the progression of the disease, is in its 20th year.
HIGH POINT, N.C., Dec. 02, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments.
Jeffrey Kindler, the former CEO of Pfizer and current CEO of Centrexion Therapeutics Corp., had been the executive chairman of vTv Therapeutics since 2015. He will continue as the chairman of the company's board of directors.
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. A stock’s float is the number ...
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 9.09% and -99.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively.
HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City on Tuesday, October 8, 2019 from 8:30 am to 10:00 am ET. The event will highlight the current treatment landscape in T1D and unmet need for additional therapies, with a focus on treatment adjuncts to insulin. To register to attend the event, contact Mike Biega, Trout Group: email@example.com or register here.
HIGH POINT, N.C., Sept. 18, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1.
The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept. 18 poster presentation of clinical data. The company is prepping for the initiation of an adaptive Phase 2/3 study in mild Alzheimer's disease patients with Type 2 diabetes.
Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program HIGH POINT, N.C.,.
HIGH POINT, N.C., Sept. 04, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered.
HIGH POINT, N.C., Aug. 06, 2019 -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally.
HIGH POINT, N.C., July 31, 2019 -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update.